

Research Activities Newsletter Nov. & Dec. 2021

In the News: Congratulations to the following awardees



Lucia Leone, Associate Professor, Department of Community Health and Health Behavior, is PI on a continuation award from the National Cancer Institute/NIH, for the project entitled, *Effectiveness and Implementation of a Research Tested Mobile Produce Market Designed to Improve Diet in Underserved Communities*. This study will continue to implement a mobile produce market program with eight organizations nationwide to determine if the effect can be replicated. It also includes development of a best-practices toolkit to help others sustainably implement the program.



Elizabeth Mietlicki-Baase, Assistant Professor, Exercise and Nutrition Sciences is PI on a new R01 award from the National Institute of Diabetes and Digestive and Kidney Diseases/NIH for a research project entitled, *Effects of Mesolimbic Amylin Signaling on Macronutrient Intake*. The project will assess mechanisms by which the hormone amylin suppresses food intake and body weight by influencing macronutrient intake, with particular focus on its actions in the ventral tegmental area (VTA), a key nucleus in the brain important for feeding and other motivated behaviors.



Katarzyna Kordas, Associate Professor, Epidemiology and Environmental Health (EEH), is PI on a new award from the US Department of Housing and Urban Development for a project entitled, *MySoRE: Mycelium-based Soil Remediation in Buffalo, NY*. The project will leverage a growing partnership among the University at Buffalo (UB), the City of Buffalo, and Grassroot Gardens of Western New York (GGWNY), a community gardening organization, to test the efficacy of dried mycelium- root structure of mushrooms - to remove Pb from soils in Buffalo.




Michael LaMonte, Research Associate Professor, Epidemiology and Environmental Health, received a new award from Fred Hutchinson Cancer Research Center/NIH, for a research project entitled, *Physical Activity to Improve CV Health in Older Women: A Pragmatic Trial*. The proposal is a competitive continuation application for the *Women's Health Initiative Strong & Healthy (WHISH)* trial (5 U01 HL122273). The *WHISH* trial is testing the hypothesis that a centralized, public health intervention designed to increase and/or maintain PA levels and reduce sitting in older women will reduce major CVD (MI, stroke, CVD death).



Jing Nie, Research Assistant Professor, Epidemiology and Environmental Health, received a new award from the Erie County Medical Center, for a research project entitled, *Support Services to ECMC ECRIP Project*. The study is about the Support Services to Erie County Medical Center Corporation ECRIP Project.



Heather Ochs-Balcom, Associate Professor, Epidemiology and Environmental Health, is PI on a continuation award from the National Cancer Institute/NIH for the project entitled, *Genetic Epidemiology of Breast Cancer Disparities in Women of African Ancestry*. The study will continue to analyze existing family- and population-based GWAS data in large-scale genetic studies to answer important questions about breast cancer disparities.



Sarahmona Przybyla, Assistant Professor, Community Health and Health Behavior and SPHHP Assistant Dean, Director of Undergraduate Public Health Programs, received a new award from the University at Buffalo's CTSA Translational Pilot Studies Program for a research project entitled, *Using the Social Ecological Model to Facilitate Pre-Exposure Prophylaxis (PrEP) Utilization for the Prevention of HIV Infection: Understanding Patient and Provider Perspectives to Reduce Health Inequities*. The primary goal of this novel project is to identify

key challenges in the PrEP care continuum and provide recommendations for intervention strategies to accelerate PrEP adoption through implementation science investigations.



Riana Pryor, Assistant Professor, Exercise and Nutrition Sciences, is PI on a new K award from the Centers for Disease Control and Prevention for the research project entitled, *Short- and Long-term Health Consequences of Workers During Consecutive Days of Heat Stress*. The proposed study will provide data to inform NIOSH's recommendations for fatigue mitigation and to meet long-term health needs of workers during consecutive days of heat stress.



Sue Ann Sisto, Chair and Professor, Rehabilitation Science and **Ghazala Saleem**, Assistant Professor, Rehabilitation Science have received a new award from the National Science Foundation (Lead PI: Filip Stefanovic, Biomedical Engineering) for the project entitled, *SEPCORPS Model - SEParating CORTical and SPinal -level Motor Control Responses Using Transcranial Direct Current Stimulation and Transcutaneous Electrical Stimulation*. The long-term objective of this project is to develop a corticospinal model that integrates sensory information for volitional movement tasks that can capture the cortical and spinal-level contributions in motor control.



Jennifer Temple, Professor of Exercise and Nutrition Sciences as PI and **Gregory Wilding**, Professor and Chair of Biostatistics, as a Co-Investigator received a new R01 award from the National Institute of Diabetes and Digestive and Kidney Diseases/NIH for the research project entitled, *The Role of Food Insecurity and Sensitization in Excess Weight Gain in Adolescents from Low to Moderate Income Households*. This study will examine a novel behavioral phenotype, sensitization to repeated intake of snack food, and its relationship with food insecurity, body weight, and weight change over time in a cohort of adolescents from moderate to low-income families.



Jean Wactawski-Wende, Dean of SPHP and SUNY Distinguished Professor of Epidemiology and Environmental Health (EEH), received the continuation award from the National Heart, Lung and Blood Institute/ NIH for the project entitled *Women's Health Initiative (WHI) – Regional Center*. As the Northeast Regional Center for the WHI, the study will collect health outcomes and new risk factor data in the postmenopausal women who have been participants since the study launched in 1993. With 70,000 remaining active participants now aged between 78 and 103 years, the extension award will continue to focus on heart failure, atrial fibrillation, VTE, coronary heart disease, peripheral arterial disease (PAD), stroke and sleep disorders, as well as assess dementia, fracture, falls, physical function and mortality. Co-Investigators from EEH are **Hailey Banack**, Research Assistant Professor, **Michael LaMonte**, Research Associate Professor, **Amy Millen**, Associate Professor, and **Heather Ochs-Balcom**, Associate Professor.



Gregory Wilding, Professor and Chair of Biostatistics, is a Co-Investigator on a new award from National Institute of Dental & Craniofacial Research/NIH, (PI: Jason Kay, Oral Biology), for the research project entitled, *A Role for Immune Cell Plasticity in Commensal Survival and Escalation of Inflammation*.

In This Issue

In the News: Congratulations to the Following Awardees	1
Grant Clinic	3
NIH Funding Opportunities	
Request for Applications (RFA)	10
Program Announcements Reviews in an Institute (PAR)	13
Individual Actions for Sustainability	24

Grant Clinic

GENERAL NOTICE

[NOT-OD-21-169](#)

New NIH "FORMS-G" Grant Application Forms and Instructions Coming for Due Dates on or after January 25, 2022

See High-level Summary of Form Changes in FORMS-G Application Packages for a full list of form changes. Applicants must use FORMS-G application packages for due dates on or after January 25, 2022, and must use FORMS-F application packages for due dates on or before January 24, 2022. Applications submitted using the wrong forms for their intended due date may be withdrawn and removed from funding consideration.

[NOT-OD-21-073](#)

Changes to the Biographical Sketch and Other Support Pages for Due Dates after May 25, 2021.

Please check the Notice for the Specific changes. A full copy of the updated Biosketch instructions can be found [here](#). Use of the updated format pages will be required for applications and Research Performance Progress Reports (RPPRs) submitted for due dates after May 25, 2021. During the transition to the new Biosketch format, NIH will not withdraw applications that include the previous Biosketch format. Beginning with applications submitted on or after January 25, 2022, failure to follow the appropriate Biosketch format may cause NIH to withdraw your application from consideration.

[NOT-OD-22-019](#)

Reminder: Notice of NIH's Encouragement of Applications Supporting Individuals from Underrepresented Ethnic and Racial Groups as well as Individuals with Disabilities

On November 22, 2019, NIH issued its latest [Notice of Interest in Diversity](#), explaining NIH's compelling interest in supporting a diverse biomedical research workforce that includes individuals from groups that are currently underrepresented in the biomedical, clinical, behavioral and social sciences, such as individuals from racial and ethnic groups that have been shown by the National Science Foundation to be underrepresented in health-related sciences on a national basis, individuals with disabilities, individuals from disadvantaged backgrounds, and women at the faculty level.

[NOT-HS-22-004](#)

AHRQ Announces Interest in Research on Digital Healthcare Safety

This Special Emphasis Notice (SEN) informs the research community that the Division of Digital Healthcare Research at the Agency for Healthcare Research and Quality (AHRQ) intends to support research regarding the safety of digital healthcare systems. Research is needed in two key areas: how the digital healthcare ecosystem can improve patient safety and how components of it can be safely used and implemented. AHRQ-funded research provides critical evidence in both areas. Applicants must clearly state in the Project Summary (abstract) and in the Specific Aims sections of the grant application that they are responding to this particular SEN (NOT-HS-22-004). Check the announcement for a list of NOFOs.

NOTICE OF INTENT TO PUBLISH

[NOT-TW-21-008](#)

Notice of Intent to Publish a Funding Opportunity Announcement for Implementation Research for Chronic Disease Prevention Across the Lifespan (R01 Clinical Trial Optional)

The Fogarty International Center (FIC) and partner National Institutes of Health (NIH) Institutes and Centers (ICs) have reorganized NIH participation in the Global Alliance for Chronic Diseases (GACD) and intends to publish Funding Opportunity Announcements (FOAs) that will utilize yearly Notices of Special Interest (NOSIs) to invite applications for implementation research on noncommunicable diseases (NCDs) in World Bank-defined low- and middle-income countries (LMICs) and marginalized Native American/Alaska Native populations in the United States. Applications will be accepted from US and LMIC institutions only.

[NOT-DA-21-081](#)

Notice of Intent to Publish a Funding Opportunity Announcement for Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional)

The National Institute on Drug Abuse (NIDA) intends to reissue PAR-19-368 "Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional)" and PAR-19-162 "Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R01-Clinical Trial Not Allowed)" to seek applications proposing innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of substance-using behaviors (defined as alcohol, tobacco, prescription, and other substances) and related disorders, prevention of substance use and HIV, and health service utilization. The FOA is expected to be published in January 2022 with an expected application due date in February 2022.

[NOT-DA-21-082](#)

Notice of Intent to Publish a Funding Opportunity Announcement for Accelerating the Pace of Drug Abuse Research Using Existing Data (R21 Clinical Trial Optional)

The National Institute on Drug Abuse (NIDA) intends to reissue PAR-19-163 "Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R21-Clinical Trial Not Allowed)" to seek applications proposing innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of substance-using behaviors (defined as alcohol, tobacco, prescription, and other substances) and related disorders, prevention of substance use and HIV, and health service utilization. The Funding Opportunity Announcement (FOA) is expected to be published in January 2022 with an expected application due date in February 2022.

[NOT-DA-21-084](#)

Notice of Intent to Publish a Funding Opportunity Announcement for NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional)

The National Institute on Drug Abuse (NIDA) intends to reissue PAR-19-259 for new applications that will support investigator initiated Research Centers of Excellence that will investigate drug abuse and addiction research. Applicants must apply and undergo peer review. The P50 Center of Excellence is expected to foster the career development and mentoring of new investigators who would be given meaningful roles to play in the Center projects. The FOA is expected to be published by Winter 2022 with an expected application due date in Fall 2022.

[NOT-OD-22-011](#)

Notice of Intent to Publish a Funding Opportunity Announcement for Center for Coordination of Analysis, Science, Enhancement, and Logistics (CASEL) in Tobacco Regulatory Science (U54 Clinical Trial Not Allowed)

The National Institutes of Health (NIH) Tobacco Regulatory Science Program (TRSP), participating NIH Institutes and Centers (ICs), and the United States Food and Drug Administration (FDA) Center for Tobacco Products (CTP) intend to reissue the Funding Opportunity Announcement (FOA) RFA-OD-17-002 "Center for Coordination of Analysis, Science, Enhancement, and Logistics (CASEL) in Tobacco Regulatory Science (U54)." The FOA is expected to be published in Winter 2022, with an expected due date in Summer 2022.

[NOT-OD-22-017](#)

Notice of Intent to Publish a Funding Opportunity Announcement for Tobacco Centers of Regulatory Science (TCORS) for Research Relevant to the Family Smoking Prevention and Tobacco Control Act (U54 Clinical Trial Optional)

The National Institutes of Health (NIH) Tobacco Regulatory Science Program (TRSP), participating NIH Institutes and Centers (ICs), and the United States Food and Drug Administration (FDA) Center for Tobacco Products (CTP) intend to reissue the Funding Opportunity Announcement (FOA) [RFA-OD-17-006 "Tobacco Centers of Regulatory Science for Research Relevant to the Family Smoking Prevention and Tobacco Control Act \(U54\)."](#) Modifications to this FOA will be the inclusion of new and revised scientific domains. In addition, Rapid Response Projects (RRPs) have been removed from this FOA. The FOA is expected to be published in Winter 2022 with an expected application due date in Summer 2022.

NOTICE OF SPECIAL INTERESTS

If you will be applying under any of the special interest topics listed below, please indicate so, including the NIH Notice number, in the Comments box of the RAS Questionnaire. The RAS staff will ensure that this information is included with the application to NIH.

[NOT-HL-22-001](#)

IDEA2Health: Innovative Data Evaluation and Analysis to Health

The purpose of this Notice of Special Interest is to stimulate research and advancement of methodologies in data science in heart, lung, blood, or sleep (HLBS) biomedical research, and ultimately translate new insights into decision-making to improve health. NHLBI will only accept applications in response to [PA-20-183](#) and [PA-20-185](#). **Applicants must include "NOT-HL-22-001" in box 4B of the SF424 R&R form.**

[NOT-CA-21-108](#)

Dietary, Physical Activity, Sedentary Behavior and Sleep Assessment Methodologies Among Infants and Young Children (Birth to 5 years) through Adults

The purpose of this NOSI is to invite investigator-initiated applications addressing approaches that improve the measurement of diet, physical activity, sedentary behavior, and sleep and their environmental influences through the development of improved methods (e.g., device-based, self-report, or other innovations). Such instruments should be based on innovative technologies (including advanced statistical and computational and/or analytical approaches), and/or integration of measurements across multiple behaviors (e.g., consumption, sleep, sedentary and active time). Studies addressing infants and young children (birth to 5 years) and individuals from underserved subgroups are especially encouraged. Submit applications for this initiative using [PA-20-185](#). **Applicants must include "NOT-CA-21-108" in box 4B of the SF424 R&R form.**

[NOT-AA-22-001](#)

Epidemiology and Prevention of Alcohol Misuse in Understudied Young Adult Populations; Military, Workforce, and Community College

It is highly encouraged that women and minorities, especially in the understudied groups, as participants in research involving human subjects are included as described in [NIH Policies for Research Involving Human Subjects](#). NIAAA also encourages that individuals who identify as members of the LGBTQ community are included as participants in the studies proposed from this solicitation. Check the FOA for a list of the announcements. **Applicants must include "NOT-AA-22-001" in box 4B of the SF424 R&R form.**

[NOT-AI-21-074](#)

Primary Caregiver Technical Assistance Supplements (PCTAS) (Admin Supp Clinical Trial Optional)

This program will help to support eligible postdoctoral scientists maintain high productivity in an NIAID-funded laboratory while engaging in primary caregiver responsibilities. At the time of supplement application, the PD(s)/PI(s) must have at least 2 years of NIAID support remaining on the parent award to be eligible for funding. Submit applications for this initiative using [PA-20-272](#). **Applicants must include "NOT-AI-21-074" in box 4B of the SF424 R&R form.**

[NOT-AR-22-007](#)

Promoting Pain Research Within the NIAMS Mission Areas

This NOSI invites research applications that focus on improving the understanding of mechanisms of acute and chronic pain, and enhancing knowledge that will help better prevent, manage and reduce pain and improve health equity of all populations suffering from acute or chronic pain caused by rheumatic, autoinflammatory, musculoskeletal, and skin diseases and conditions within the NIAMS mission. Check the FOA for a list of the announcements. **Applicants must include “NOT-AR-22-007” in box 4B of the SF424 R&R form.**

[NOT-CA-22-001](#)

Improving Outcomes in Cancer Treatment-Related Cardiotoxicity

NCI and NHLBI are interested in grant applications with oncology and cardiology collaborative approaches that address the research gaps as outlined in Shelburne, et al. [2014](#) and [2019](#). Applications addressing pediatric and adult needs are of interest. Check the FOA for a list of the announcements. **Applicants must include “NOT-CA-22-001” in box 4B of the SF424 R&R form.**

[NOT-DA-21-020](#)

Evaluation of Sex Differences on HIV-associated Comorbidities in the Context of Stimulant Use

The goal of this Notice is to encourage applications focusing on the understanding of the biological basis of sex differences in HIV neuropathogenesis and the comorbidity of HIV with misuse of stimulants, including amphetamine, methamphetamine, cocaine, and nicotine. Studies at single cell and CNS circuits levels and in live behaving animals are encouraged. Check the FOA for a list of the announcements. **Applicants must include “NOT-DA-21-020” in box 4B of the SF424 R&R form.** This NOSI will expire on January 08, 2025

[NOT-DA-21-064](#)

International Research Collaboration on Drug Abuse and Addiction Research

The purpose of this notice is to encourage collaborative research applications that take advantage of opportunities outside of the United States. Applications examining all areas of NIDA-supported research addressing the causes, consequences, treatment, recovery, and prevention of drug use, misuse, and addiction are encouraged. Projects may be conducted through newly formed or well-established partnerships between investigators in a U.S.-based institution and scientists working in another country. All NIH grant applications for research to be conducted outside the United States must establish that the proposal takes advantage of unique research opportunities in other countries, speeds scientific discovery, and advances U.S. health science. Check the FOA for a list of the announcements. **Applicants must include “NOT-DA-21-064” in box 4B of the SF424 R&R form.** This NOSI will expire on September 08, 2024.

[NOT-OD-21-127](#)

Electronic Nicotine Delivery Systems (ENDS) and Alternative Nicotine and Tobacco Delivery Systems: Basic Mechanisms of Health Effects

The Office of Disease Prevention and participating ICOs are issuing this Notice to communicate our interest in research examining how electronic nicotine delivery systems (ENDS) affect normal and disease states relevant to human cells, tissues, organs, and behaviors. Research on alternative nicotine and tobacco delivery systems [e.g., heated tobacco products (also called heat-not-burn)] will also be considered. Studies exclusively examining smokeless tobacco or combustible tobacco products (e.g., cigarettes, cigars) will be considered non-responsive. Check the FOA for a list of the announcements. **Applicants must include “NOT-OD-21-127” in box 4B of the SF424 R&R form.**

[NOT-OD-22-022](#)

Electronic Nicotine Delivery Systems (ENDS) and Alternative Nicotine and Tobacco Delivery Systems: Basic Mechanisms of Health Effects

This NOSI encourages feasibility and pilot research, as well as efficacy and effectiveness research on new or adapted interventions. Investigators must carefully review the specific research interests of NIH Institutes, Centers, and Offices that are participating in this NOSI. Responsive studies should make use of human cells or specimens, and where appropriate, may utilize cell or animal models that are relevant to humans and well justified. Check the FOA for announcements. **Applicants must include “NOT-OD-22-022” in box 4B of**

the SF424 R&R form.

[NOT-OD-22-023](#)

Electronic Nicotine Delivery Systems (ENDS) and Alternative Nicotine and Tobacco Delivery Systems: Population, Clinical and Applied Prevention Mechanisms of Health Effects

This Notice encourages studies that seek to address gaps in our understanding related to population-based, clinical, and applied prevention research related to ENDS and heated tobacco products. The goal of these studies will be to better understand the impact of use of these products on the prevention of disease or the risk of disease (including cancer, dental, oral, and/or craniofacial). Increased comprehension about patterns of ENDS use with other tobacco products and how they affect addiction to nicotine, alcohol, and other drugs is sought, as well as understanding the effects of second- and third-hand exposure to the aerosols. Check the FOA for a list of the announcements. **Applicants must include “NOT-OD-22-023” in box 4B of the SF424 R&R form.**

[NOT-OD-22-031](#)

Research on the Health of Women of Understudied, Underrepresented and Underreported (U3) Populations (Admin Supp Clinical Trial Optional)

The Office of Research on Women's Health announces the availability of administrative supplements to support research highlighting health inequities among women in the US who are underrepresented, understudied, and underreported (U3) in biomedical research. Robust studies exploring sex and gender influences and social determinants of health are needed to reduce inequities. The proposed research must address at least one objective from strategic goals 1, 2 or 3 of the “2019-2023 Trans-NIH Strategic Plan for Women's Health Research, Advancing Science for the Health of Women.” Submit applications for this initiative using [PA-20-272](#) . **Applicants must include “NOT-OD-22-031” in box 4B of the SF424 R&R form.**

[NOT-CA-21-074](#)

Early-life Factors and Cancer Development Later in Life

This NOSI seeks to further support research on early-life factors and cancer development later in life. Studies proposed in response to this NOSI should focus on human studies, but may incorporate research using animal models, especially in elucidating mechanisms relevant in humans. Check the FOA for a list of the announcements. **Applicants must include “NOT-CA-21-074” in box 4B of the SF424 R&R form.** This NOSI will expire on March 08, 2024.

[NOT-CA-21-085](#)

New Information Technology-Enabled Care Delivery Models to Improve Depression Care in Cancer

This Notice of Special Interest (NOSI) highlights interest of the National Cancer Institute (NCI)'s Division of Cancer Control and Population Sciences in receiving investigator-initiated applications for conducting research on the design and implementation of new information technology (IT)-enabled care delivery models to improve depression-related care in cancer. Check the FOA for a list of the announcements. **Applicants must include “NOT-CA-21-085” in box 4B of the SF424 R&R form.**

[NOT-HD-21-027](#)

Navigating Pediatric to Adult Health Care: Lost in Transition

The purpose of this NOSI is to encourage applications in high-priority research areas related to pediatric health care transition for youth with chronic physical/medical conditions or intellectual/developmental disabilities. Research applications that will advance our understanding of promising practices designed to facilitate successful health care transitions (HCT) from pediatric to adult care settings as well as barriers and facilitators to such transition are encouraged. The ultimate goal is to improve care quality and patient and family outcomes during and after HCT. Check the FOA for a list of the announcements. **Applicants must include “NOT-HD-21-027” in box 4B of the SF424 R&R form.**

[NOT-AI-21-057](#)

HIV/AIDS in the Era of COVID-19: When Pandemics Collide

This NOSI encourages research on the impact and strategies needed to adapt the HIV/AIDS response through agile and innovative support of prevention and care and the maintenance of sustained HIV viral suppression during the coronavirus disease 2019 (COVID-19) pandemic. Submit applications for this

initiative using PA-20-185 & [PA-20-195](#). **Applicants must include “NOT-AI-21-057” in box 4B of the SF424 R&R form.**

[NOT-AA-21-028](#)

Public Policy Effects on Alcohol-, Cannabis-, Tobacco-, and Other Drug-Related Behaviors and Outcomes

This Notice is intended to support innovative research to examine policy effects that have the potential to lead to meaningful changes in public health. Research projects that may be supported include, but are not necessarily limited to: causal analyses of the effects of one or multiple public policies; evaluations of the effectiveness of specific public policies as tools for improving public health through their effects on alcohol-, cannabis-, tobacco-, and other substance-related behaviors and outcomes; studies of disparities in policy effects and the role of policy in exacerbating or potentially reducing health disparities; and research to advance methods and measurement used in studying relationships between public policies and alcohol-, cannabis-, tobacco-, and other substance-related behaviors and outcomes. **Applicants must include “NOT-AA-21-028” in box 4B of the SF424 R&R form.**

[NOT-DA-21-012](#)

Women and Sex/Gender Differences in Drug and Alcohol Abuse/Dependence

The purpose of this Notice is to inform potential applicants of the National Institute on Drug Abuse (NIDA) special interest in grant applications to conduct rigorous basic, translational and/or clinical research to: (1) advance identification of sex and/or gender differences in risk for substance use disorders or the response or medical consequences of alcohol or substance misuse to uncover the mechanisms of those differences, and to conduct translational research on those differences, and (2) advance research specific to women or highly relevant to women. Both preclinical and clinical studies are sought across all areas of drug and alcohol research. **Applicants must include “NOT-DA-21-012” in box 4B of the SF424 R&R form.**

[NOT-CA-21-071](#)

Expanding Cancer Control Research in Persistent Poverty Areas

The purpose of this Notice is to inform potential applicants about the National Cancer Institute (NCI)'s special interest in providing resources to support highly collaborative, multi-disciplinary Program Projects (P01s) that focus on the development and conduct of cancer control research in low-income and/or underserved populations living in persistent poverty (PP) areas. NCI is interested in programs that address the challenges and opportunities related to working in partnership with local clinics and other health or public health-related organizations to enhance the prevention of cancer and delivery of cancer care strategies to reduce the burden of cancer in PP areas. **Applicants must include “NOT-CA-21-071” in box 4B of the SF424 R&R form.** This NOSI will expire on May 08, 2023.

[NOT-DA-21-003](#)

Leveraging Longitudinal Studies in Animal Models to Identify Neural Mechanisms of Vulnerability and Resilience to Substance Use Disorder

NIDA seeks to stimulate research in non-human species aimed at modeling environmental and/or biological risk factors for SUD to elucidate neural and cognitive developmental mechanisms that may mediate, moderate, or predict the effects of these factors on subsequent emergence of SUD-related behaviors. Use of longitudinal designs and developmental-stage-appropriate paradigms are strongly encouraged. **Applicants must include “NOT-DA-21-003” in box 4B of the SF424 R&R form.** This NOSI will expire on September 08, 2024.

[NOT-AG-21-015](#)

Ageing-Relevant Behavioral and Social Research on Coronavirus Disease 2019 (COVID-19)

This Notice of Special Interest (NOSI) is to highlight the continuing need for behavioral, psychological, social, and economic research on SARS-CoV-2 and coronavirus disease 2019 (COVID-19). There is a need for ongoing research on the longer-term effects of COVID-19 on the health and well-being of those infected, those caring for the sick, and many others whose lives were disrupted by the pandemic and its associated mitigation and prevention strategies. **Applicants must include “NOT-AG-21-015” in box 4B of the SF424 R&R form.** This NOSI will expire on May 08, 2023.

[NOT-CA-21-031](#)

Understanding the Effects of Cancer and Cancer Treatment on Aging Trajectories and Aging Outcomes

The purpose of this Notice of Special Interest is to solicit investigator-initiated applications that aim to better understand the effects of a cancer diagnosis and subsequent cancer treatment on aging trajectories and aging outcomes. Investigations in understudied populations, including those that are medically underserved, are encouraged. This notice applies to due dates on or after *March 8, 2021*, and subsequent receipt dates through January 7, 2024. **Applicants must include “NOT-CA-21-031” in box 4B of the SF424 R&R form.** This NOSI will expire on January 08, 2024.

[NOT-DA-21-011](#)

Effects of Smoking and Vaping on the Risk and Outcome of COVID-19 Infection

The purpose of this notice is to communicate NIDA’s interest in supporting research on **the effects of smoking or vaping tobacco or marijuana on the risk of acquiring COVID-19 and the clinical course of the infection.** This Notice is a reissuance of [NOT-DA-20-084](#). Research applications focusing on individuals who smoke or vape either marijuana and/or tobacco to determine: 1) the risk of contracting a COVID-19 infection, 2) the effects on asymptomatic COVID-19 infected persons, and 3) the course of the COVID-19 infection are interested. **Applicants must include “NOT-DA-21-011” in box 4B of the SF424 R&R form.** This NOSI will expire on September 08, 2024.

[NOT-DA-21-017](#)

Medical Consequences of Smoking & Vaping Drugs of Abuse in Individuals with HIV and COVID-19

NIDA is interested in receiving research applications focusing on individuals with HIV who smoke or vape marijuana, tobacco, cocaine and/or methamphetamine to determine the long-term effects of their use among individuals with HIV and COVID-19. **Applicants must include “NOT-DA-21-017” in box 4B of the SF424 R&R form.** This NOSI will expire on September 08, 2024.

[NOT-DE-21-019](#)

Basic and Translational Oral Health Research Related to HIV/AIDS

The National Institute of Dental and Craniofacial Research (NIDCR) is issuing this Notice of Special Interest (NOSI) to encourage basic and translational research into mechanisms of HIV transmission, persistence, and pathogenesis in the oral cavity and its associated co-morbidities. **Applicants must include “NOT-DE-21-019” in box 4B of the SF424 R&R form.** This NOSI will expire on May 08, 2023.

[NOT-HL-21-025](#)

Examining Effects of HIV Pre-Exposure Prophylaxis (PrEP) on Heart, Lung, Blood, and Sleep Function

The purpose of this notice is to stimulate research focused on elucidating the impact of HIV pre-exposure prophylaxis (PrEP) on heart, lung, blood, and sleep (HLBS) conditions. Projects ranging from basic mechanistic studies to implementation investigations, including clinical studies and NIH-defined clinical trials fitting the definition of mechanistic clinical trials/BESH research, may be considered responsive to the Notice. Submit applications for this initiative using [PA-20-183](#) & [PA-20-185](#). **Applicants must include “NOT-HL-21-025” in box 4B of the SF424 R&R form.** This NOSI will expire on May 08, 2025

NIH Funding Opportunities

NIH Funding Opportunities: Request for Applications (RFA)

FEBRUARY 2022 DUE DATES

[RFA-AG-22-026 \(F99/K00 Clinical Trial Not Allowed\)](#)

Transition to Aging Research for Predoctoral Students

NIA invites outstanding graduate students from a wide range of broad research areas who are interested in receiving aging-related postdoctoral training to apply for this award. This Funding Opportunity Announcement (FOA) fosters the development of research and clinician scientists in the following areas:

genetic, biological, clinical, epidemiological, neuroscience, behavioral, social, and economic research on aging, both basic and translational. This two-phase award will allow awardees to complete doctoral dissertation projects and provides a variety of training supports to facilitate the smooth transition of doctoral graduates into competitive, aging-focused postdoctoral positions. **Application Due:** February 03, 2022

[RFA-DA-22-028 \(R01 - Clinical Trial Optional\)](#)

[RFA-DA-22-039 \(R21 - Clinical Trial Optional\)](#)

Pharmacokinetics (PK) and Pharmacodynamics (PD) of THC in Cannabis and Cannabis Products

The purpose of this Funding Opportunity Announcement (FOA) is to support human and animal research on the pharmacokinetic (PK) and pharmacodynamic (PD) effects of Δ^9 -tetrahydrocannabinol (THC) that is present in cannabis and cannabis products. **Application Due Date:** February 09, 2022

[RFA-DA-22-018 \(R41/R42 CLINICAL TRIAL NOT ALLOWED\)](#)

[RFA-DA-22-023 \(R43/R44 CLINICAL TRIAL NOT ALLOWED\)](#)

Advancing Validated Drug Targets for Substance Use Disorders

This Funding Opportunity Announcement (FOA) seeks grant applications from small business concerns (SBCs) to continue research projects with robustly validated targets for Substance Use Disorders (SUDs). This FOA will provide funding for projects entering at either assay development (AD), lead identification (LI), lead optimization (LO), or preclinical development (PCD) stages to allow for the ultimate goal of successfully completing Investigational New Drug-enabling activities. **Application Due:** February 18, 2022

[RFA-CA-21-060 \(K99/R00 - Independent Clinical Trial Not Allowed\)](#)

[RFA-CA-21-061 \(K99/R00 - Independent Clinical Trial Required\)](#)

[RFA-CA-21-062 \(K99/R00 - Independent Basic Experimental Studies with Humans Required\)](#)

NCI Pathway to Independence Award for Outstanding Early-Stage Postdoctoral Researchers

The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of data science and cancer control science are especially encouraged to apply. **Application Due:** February 28, 2022

MARCH 2022 DUE DATES

[RFA-HD-23-005 \(R01 Clinical Trial Optional\)](#)

Promoting Reproductive Health for Adolescents and Adults with Disabilities

The proposed research should have the potential to either 1) reduce barriers to appropriate reproductive (gynecologic and urologic) care experienced by PWD (including access to care providers and appropriate counseling and screening during visits); or 2) increase effective use of existing medications and devices for contraception and infectious disease prevention by PWD. **Application Due Date:** March 30, 2022

[RFA-HD-22-023 \(R01 Clinical Trial Optional\)](#)

Elucidating the Role of Nutrition in Care and Development of Preterm Infants

The purpose of this FOA is to invite applications to address priority gaps in our understanding of the role of nutrition in the care and development of preterm infants. These gaps include Data to develop nutrient specifications for preterm infants, Clinical issues in meeting nutritional needs in preterm infants across the relevant stages of development. Current standards for assessing nutritional status and the impact of infant feeding. **Application Due Date:** March 30, 2022

[RFA-HD-22-017 \(R01 Clinical Trial Required\)](#)

Home and Community-Based Physical Activity Interventions to Improve the Health of Wheelchair Users

The purpose of this funding opportunity announcement (FOA) is to request applications to develop/adapt and test physical activity interventions for individuals who use wheelchairs due to physical disability. The goal of the proposed interventions should be to safely prevent, or reverse chronic conditions associated with low physical activity such as diabetes, cardiovascular disease, and obesity. Interventions that could be

applied or easily adapted to large populations of wheelchair users and used in multiple settings are a priority. **Application Due Date:** March 30, 2022

[RFA-DK-21-018 \(R01 Clinical Trial Required\)](#)

Pilot and Feasibility Studies to Improve Technology Adoption and Reduce Health Disparities in Type 1 Diabetes Mellitus

The purpose of this FOA is to support pilot and feasibility trials of interventions designed to improve technology adoption in individuals from underrepresented backgrounds with type 1 diabetes mellitus (T1D). Through successful execution, these pilot and feasibility trials should provide feasibility data for larger, pragmatic trials with the overarching goal of reducing health disparity in T1D through improving technology usage in individuals from minority racial and ethnic backgrounds. **Application Due Date:** March 03, 2022

[RFA-DK-21-025 \(R01 Clinical Trial Optional\)](#)

Pediatric Obesity Discovery Science Research to Improve Understanding of Risk and Causal Mechanisms for Obesity in Early Life

The purpose of this FOA is to support innovative, discovery research studies to better characterize early- life risk factors and elucidate underlying causal mechanisms through which these risk factors contribute to the development of obesity during infancy and early childhood. Studies should aim to understand biological mechanisms that mediate behavioral and/or metabolic risk for obesity development in young children and how risk may be modified by other contributors such as psychosocial, contextual, and/or environmental factors. This FOA encourages multidisciplinary teams of scientists including, but not limited to those with expertise in basic, translational, clinical, and behavioral research. **Application Due Dates:** March 08, 2022

MULTIPLE DUE DATES

[RFA-DA-22-040 \(R01 Clinical Trial Optional\) High Priority HIV and Substance Use Research](#)

The purpose of this Funding Opportunity Announcement (FOA) is to support high priority research at the intersection of HIV and substance use. This FOA invites innovative research projects with the potential to open new areas of HIV/AIDS research and/or lead to new avenues for prevention, treatment and cure of HIV among people who use drugs (PWUD). Applications submitted under this FOA are required to have a detailed research plan, preliminary data, and a clear description of the nexus with substance use. This FOA is open to both individual researchers and research teams and includes all areas of research from basic science to clinical and implementation research. **Application Due Dates:** Monthly due dates; refer to RFA.

[RFA-CA-22-003 \(R61 Clinical Trial Not Allowed\)](#)

Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research

This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, or epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. **Application Due Dates:** April 22, 2022, September 22, 2022

[RFA-HL-22-010 \(K01 Independent Clinical Trial Required\)](#)

[RFA-HL-22-011 \(K01 Independent Clinical Trial Not Allowed\)](#)

Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research

This FOA invites applications to enhance the pool of highly trained investigators from diverse backgrounds, including those from groups underrepresented in research areas of interest to the NHLBI. The career development will take place under the guidance of an experienced mentor in the biomedical, behavioral or clinical sciences leading to research independence. It is targeted toward individuals whose basic, clinical, and translational research interests are grounded in the advanced methods and experimental approaches needed to solve problems related to cardiovascular, pulmonary, and hematologic diseases and sleep disorders in the general and health disparities populations. **Application Due Dates:** February 11, 2022, October 13, 2022, February 14, 2023, October 13, 2023, February 13, 2024

[RFA-HL-23-004 \(R35 Clinical Trial Optional\) NHLBI Outstanding Investigator Award \(OIA\)](#)

The purpose of the NHLBI Outstanding Investigator Award (OIA) is to promote scientific productivity and

innovation by providing long-term support and increased flexibility to experienced Program Directors/Principal Investigators (PD/PIs) who are currently PD/PIs on at least two NHLBI R01-equivalent awards and whose outstanding record of research demonstrates their ability to make major contributions to heart, lung, blood and sleep (HLBS) research. The OIA is intended to support a research program, rather than a research project, by providing the primary and most likely sole source of NHLBI funding on individual grant awards. The OIA will support the research program of NHLBI-funded investigators for up to seven years. **Application Due Dates:** February 15, 2022, February 15, 2023, February 15, 2024

[RFA-HL-23-005 \(R35 Clinical Trial Optional\) NHLBI Emerging Investigator Award \(EIA\)](#)

The purpose of the NHLBI Emerging Investigator Award (EIA) is to promote scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program Directors/Principal Investigators (PD/PIs) who are currently PD/PIs on at least two NHLBI R01-equivalent awards and whose outstanding record of research demonstrate their ability to make major contributions to heart, lung, blood and sleep (HLBS) research. The EIA will support the research program of NHLBI-funded investigators for up to seven years. **Application Due Dates:** February 15, 2022, February 15, 2023, February 15, 2024

[RFA-NS-20-008 \(R41/R42\); RFA-NS-20-010 \(R43/R44\)](#) clinical trial required

[RFA-NS-20-009 \(R41/R42\); RFA-NS-20-011 \(R43/R44\)](#) clinical trial not allowed

HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management

These FOAs aim to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management. They are focused on applications directed at improving pain treatment, including the development of new non-addictive medications and devices and objective pain measurement. In addition, NIH is interested in new screening tools and models focused specifically on pain and development of pain therapies. **Application Due Dates:** January 6, 2022, April 6, 2022, September 8, 2022

[RFA-NS-19-043 \(K99/R00\)](#) clinical trial not allowed

[RFA-NS-19-044 \(K99/R00\)](#) independent clinical trial required

BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity

This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The BRAIN Initiative is aimed at revolutionizing our understanding of the human brain. By accelerating the development and application of innovative technologies, researchers will be able to produce a new dynamic picture of the brain that, for the first time, will show how individual cells and complex neural circuits interact in both time and space.

Application Due Dates: February 10, 2022, June 8, 2022, October 11, 2022

[RFA-OD-20-008 \(K01\)](#) clinical trial not allowed

[RFA-OD-20-011 \(K01\)](#) clinical trial required

Mentored Research Scientist Career Development Award in Tobacco Regulatory Research

This award provides support and protected time (2-5 years) for an intensive, supervised career development experience in biomedical, behavioral, and social science research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing and that will lead to research independence. Candidates for the K01 award must have a research or health- professional doctoral degree. **Application Due Date:** July 8, 2022

[RFA-OD-20-009 \(K99/R00\)](#) clinical trial not allowed

[RFA-OD-20-010 \(K99/R00\)](#) clinical trial required

Pathway to Independence Award in Tobacco Regulatory Research

This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. This program will provide independent research support during this transition in order to help awardees launch competitive, independent research careers.

Application Due Date: July 8, 2022

[RFA-DA-19-019 \(R43/R44\)](#) clinical trial optional

[RFA-DA-19-020 \(R41/R42\)](#) clinical trial optional

America's Startups and Small Businesses Build Technologies to Stop the Opioid Crisis

These FOAs invite applications from US small business concerns to develop technologies to provide science-and research-based solutions to the opioid emergency. **Application Due Date:** September 8, 2022

[RFA-ES-19-011 \(R21\)](#) – clinical trial not allowed

Mechanism for Time-Sensitive Research Opportunities in Environmental Health Sciences

This FOA supports novel environmental health research in which an unpredictable event or policy change provides a limited window of opportunity to collect human biological samples or environmental exposure data. A distinguishing feature of an appropriate study is the need for rapid review and funding, substantially shorter than the typical NIH grant review/award cycle, for the research question to be addressed and swiftly implemented. **Application Due Dates:** Monthly due dates; please refer to the RFA.

[RFA-DK-20-032](#) (R34 Clinical Trial Required)

Pilot and Feasibility Studies to Facilitate the Use of Diabetes Self-Management Education and Support to Improve Diabetes Care

The FOA is to test an innovative and pragmatic approach to address barriers to and facilitate greater use of diabetes self-management education and support (DSMES) by people living with diabetes mellitus. Research applications should engage key stakeholders in cultivating a practical and sustainable strategy with the potential for dissemination. The pilot trial of the proposed strategy should be designed to generate preliminary data in support of a future, full-scale trial to study broader dissemination and implementation to expand the use of DSMES. **Application Due Dates:** June 22, 2022, June 22, 2023.

[RFA-AI-21-023](#) (R01 Clinical Trial Optional)

Respond: Epidemiology to End the HIV Epidemic (RESPOND: EEE)

The purpose of FOA is to support applications that address the RESPOND pillar of the *Ending the HIV Epidemic: A Plan for America* (EHE) initiative. The objective is to better understand HIV susceptibility and ongoing transmission in the United States (U.S.) using local and population-level epidemiology in collaboration with implementing partners. Data generated through this research will inform intervention approaches and facilitate more timely evaluation of context-specific HIV control strategies towards the goal of ending the HIV epidemic in the U.S. **Application Receipt Dates:** Multiple dates, see announcement.

[RFA-EB-21-001](#) (R01 Clinical Trial Optional)

Technology Development to Reduce Health Disparities

This program seeks advances in medical technologies to reduce health disparities associated with diseases, illnesses, and conditions of public health importance. This announcement encourages applications to develop medical devices, imaging systems, robotic systems, biomaterial interfaces, synthetic biological systems, mathematical and modeling solutions, and other technologies to address the healthcare needs of populations that experience health disparities. **Application Due Dates:** February 11, 2022, January 26, 2023, January 26, 2024

NIH Funding Opportunities: Program Announcements Reviews in an Institute (PAR)

[PAR-21-337](#) (T32 Clinical Trial Not Allowed)

Limited Competition: Ruth L. Kirschstein National Research Service Award (NRSA) Predoctoral Research Training Grant for the Clinical and Translational Science Awards (CTSA) Program

The National Center for Advancing Translational Sciences (NCATS) will award Ruth L. Kirschstein National Research Service Award (NRSA) Predoctoral Institutional Research Training Grants for the Clinical and Translational Science Awards (CTSA) Program (T32) to eligible institutions to enhance predoctoral research training of individuals seeking a PhD or an equivalent research health professional degree and help ensure a heterogeneous pool of clinical and translational scientist trainees who are equipped with the knowledge, skills and abilities to advance diagnostics, therapeutics, clinical interventions, and behavioral modifications aimed at improving health. **Application Due Dates:** Multiple dates, see announcement.

[PAR-21-338](#) (T32 Clinical Trial Not Allowed)

Limited Competition: Ruth L. Kirschstein National Research Service Award (NRSA) Postdoctoral Research Training Grant for the Clinical and Translational Science Awards (CTSA) Program

The proposed institutional research training program may complement other ongoing research training and career development programs at the applicant institution but must be clearly distinct from related programs currently receiving Federal support. This FOA does not allow appointed Trainees to lead an independent clinical trial but does allow them to obtain research experience in a clinical trial on which the PI is a mentor or co-mentor. **Application Due Dates:** Multiple dates, see announcement.

[PAR-21-349](#) (R01 Basic Experimental Studies with Humans Required) [PAR-21-350](#) (R01 Clinical Trials Not Allowed)

[PAR-21-352](#) (R01 Clinical Trial Required)

Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery

This funding opportunity announcement (FOA) invites research projects that seek to model the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in health, illness, recovery, and overall wellbeing. **Application Due Dates:** Multiple dates, see announcement.

[PAR-21-344](#) (R01 - Clinical Trial Optional)

Interventions for Stigma Reduction to Improve HIV/AIDS Prevention, Treatment and Care in Low- and Middle- Income Countries

This initiative will support intervention research on a) novel stigma reduction strategies that link to increase in care-seeking behavior and/or decrease in transmission, b) reducing the impact of stigma on adolescent and/or youth health, c) strategies to cope with the complex burden of stigmatization due to HIV and one or more comorbidities/coinfections, d) reducing the effects of stigma on, and/or by, family members or care givers of PLWH and e) development of innovative and improved stigma measurement in the context of implementation of a stigma-reduction intervention. The overall goals are to understand how to reduce stigma as a factor in HIV transmission, to eliminate or mitigate the aspects of stigma that limit beneficial health outcomes for the infected and at-risk individuals and communities, and to conduct exploratory studies to determine the feasibility of stigma-reduction interventions related to HIV prevention, treatment and/or care in Low and Middle-Income Countries (LMICs). **Application Due Date:** December 20, 2022

[PAR-21-336](#) (K12 Clinical Trial Optional)

Limited Competition: Mentored Research Career Development Program Award in Clinical and Translational Science Awards (CTSA) Program

The purpose of this Funding Opportunity Announcement (FOA) is to encourage institutions to propose creative and innovative institutional research career development programs designed to prepare an outstanding heterogeneous pool of promising later stage postdoctoral fellows and junior faculty scholars in clinical and translational science who have made a commitment to independent research careers (i.e., tenure-track or equivalent faculty positions), and to facilitate their timely transition to more advanced support mechanisms, e.g., K08, K23, R01, R03, etc. Applicants must submit both a UM1 application to [PAR-21- 293: Clinical and Translational Science Award](#) and a K12 application to this FOA.

Application Receipt Dates: Multiple dates, see announcement.

[PAR-21-339](#) (R25 - Clinical Trial Not Allowed)

Limited Competition: NCATS Clinical and Translational Science Award (CTSA) Program Research Education Grants Programs

This FOA will provide support to recipients of Clinical and Translational Science Awards (CTSA) for creative educational activities with a primary focus on research experiences designed to ensure that the participants receive exposure to the scientific and operational principles underlying each step of the translational process so that they can apply these principles to clinical and translational science research areas such as:

1) pre-clinical research, 2) clinical research, 3) clinical implementation, and 4) public health.

Application Receipt Dates: Multiple dates, see announcement.

[PAR-21-303](#) (R21/R33 - Clinical Trial Optional)

Mobile Health: Technology and Outcomes in Low- and Middle-Income Countries

The purpose of this Funding Opportunity Announcement (FOA) is to encourage exploratory/developmental research applications that propose to study the development, validation, feasibility, and effectiveness of innovative mobile health (mHealth) interventions or tools specifically suited for low- and middle-income countries (LMICs) that utilize new or emerging technology, platforms, systems, or analytics. The overall goal of the program is to catalyze innovation through multidisciplinary research that addresses global health problems, develop an evidence base for the use of mHealth technology to improve clinical and public health outcomes, and strengthen mHealth research capacity in LMICs.

Application Due Date: November 05, 2022

[PAR-21-281](#) (R01 Clinical Trials Not Allowed)

Dyadic Interpersonal Processes and Biopsychosocial Outcomes

This funding opportunity announcement (FOA) invites basic and/or methodological research projects that seek to illuminate or measure independent and interdependent health-related effects within dyads. For the purpose of this FOA, a *dyad* is a unit of two individuals whose interactions and influences on one another are nested within larger social contexts and networks. Both animal and human subjects research projects are welcome. **Application Due Dates:** February 05, 2022, February 05, 2023

[PAR-21-287](#) (R01 Clinical Trial Optional)

Effectiveness of School-Based Health Centers to Advance Health Equity

The purpose of this Funding Opportunity Announcement is to support research that investigates the effectiveness of school-based health centers (SBHCs) as a health services care delivery model to address the needs of school-aged children from populations with health disparities (hence, underserved youth).

Application Due Dates: Standard dates apply.

[PAR-21-286](#) (R50 Clinical Trial Not Allowed)

NCI Research Specialist (Core-based Scientist) Award

The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional scientists who want to continue to pursue research within the context of an existing NCI-funded basic, translational, clinical, or population science cancer research program, but not serve as independent investigators. These scientists, such as researchers within a core/shared resource/central scientific support, are vital to sustaining the biomedical research enterprise.

Application Due Date: March 17, 2022.

[PAR-21-168](#) (R25) Clinical Trial Not Allowed

Summer Research Education Experience Program

The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. R25 programs that propose at least 8 weeks, but fewer than 15 weeks, of full-time research experiences during the summer may request continued part-time support for the participants to work on their research projects during the school year, up to the equivalent of a total of 15 weeks of full-time participation, as long as the entire research experience is completed within a 12-month period. Applications that demonstrate the potential to impact students and teachers from diverse backgrounds are particularly encouraged.

Application Due Dates: March 17, 2022, March 17, 2023, and March 19, 2024

[PAR-20-236](#)(R25) Clinical Trials Not Allowed

Providing Research Education Experiences to Enhance Diversity in the Next Generation of Substance Use and Addiction Scientists

This FOA invites applications from established researchers with a record of NIH funding, who can demonstrate that they have successfully guided previous early career scientists to independent research careers and are able to direct an educational research capacity building program. This R25 program intends to strengthen the pipeline of individuals in biomedical, behavioral, and clinical substance use and addiction research across various stages of the research pipeline to enhance the number of independently funded investigators from diverse backgrounds. **Application Due Dates:** March 15, 2022, August 10, 2022, November 15, 2022, March 15, 2023, August 10, 2023, November 15, 2023

[PAR-20-310 \(R01\)](#) Clinical Trial Optional

Health Services Research on Minority Health and Health Disparities

The primary interest of this FOA is research on system-wide health services research that encompasses the diversity of individuals served within these health care systems. It is expected that projects will include patient or participant samples that are representative of the population served by the health care system(s) to be studied. Projects that include populations that identify across more than one health disparity group are encouraged. **Application Due Dates:** March 17, 2022, November 17, 2022, February 17, 2023.

[PAR-20-302\(R01\)](#) [PAR-20-303 \(R21\)](#)

Tobacco Control Policies to Promote Health Equity

Specifically, this FOA aims to stimulate scientific inquiry focused on innovative state and local level tobacco prevention and control policies. The long-term goal of this FOA is to reduce disparities in tobacco-related cancers, and in doing so, to promote health equity among all populations.

Application Due Dates: [Standard dates](#) apply.

[PAR-20-289 \(R25\)](#)-Clinical Trial Not Allowed

NIAID Research Education Program

The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. The PD/PI should be an established investigator in the scientific area in which the application is targeted and capable of providing both administrative and scientific leadership to the development and implementation of the proposed program. The PD/PI will be expected to monitor and assess the program and submit all documents and reports as required. Participants are limited to the following individuals:

- Graduate/health professional (e.g., medical) students, medical residents, postdoctoral fellows, and/or early-career faculty. For this program "early career faculty" must be within the first 8 years of their first faculty appointment.
- Participants may be from a single career stage, or programs may propose to bridge several career stages of participants.
- Participants may be early career researchers that are moving into new research areas relevant to the NIAID research.

Note that high school and undergraduate students, postbaccalaureate fellows, and master's level graduate students may not be supported as participants under this FOA. **Application Due Date:** December 7, 2022

[PAR-21-027 \(R01\)](#) Clinical Trial Not Allowed

Multidisciplinary Approaches to HIV-Associated Comorbidities and Prioritizing Intervention Targets

This FOA seeks applications for comprehensive systems biology studies using multidisciplinary team science to identify common, overlapping etiologies of HIV-associated comorbidities. Ultimately, the goal is to identify targets for intervention to mitigate multiple comorbidities associated with HIV infection.

Application Due Dates: January 7, 2022, May 7, 2022, January 7, 2023.

[PAR-21-044 \(X01\)](#)

Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access

This Funding Opportunity Announcement (FOA) allows investigators to apply for access to the Population Assessment of Tobacco and Health (PATH) Study biospecimens for use in conducting tobacco-related research studies. The PATH Study collects data from adults and youth. Investigators proposing meritorious and feasible studies consistent with [PATH Study objectives](#) and/or research priorities for tobacco regulatory science will be given highest priority for access to PATH Study biospecimens.

Application Due Dates: April 29, 2022, October 31, 2022, April 28, 2023, October 31, 2023.

[PAR-20-307\(P30\)](#) Clinical Trial Optional

[PAR-20-308\(P30\)](#) Clinical Trial Optional

Developmental AIDS Research Centers on Mental Health and HIV/AIDS

D-ARC awards permit the centralized coordination of affiliated research activities, foster the development of scientific innovations and new collaborations, encourage interdisciplinary research, and facilitate the dissemination of public health advances to implementing agencies, academia, affected communities, and policymakers. These Centers must have the potential to support research over a range of cross-cutting

areas that may include biological, biomedical, behavioral, neuroscience, mental health, prevention, clinical sciences, and implementation science research.

Application Due Dates: August 25, 2022, August 25, 2023.

[PAR-21-033](#) (R01 Clinical Trial Required)

National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis

The purpose of this FOA is to seek research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of the National Cancer Institute's (NCI) Division of Cancer Treatment and Diagnosis (DCTD) and the Office of HIV and AIDS Malignancies (OHAM, Office of the Director). Applicants are strongly encouraged to consult the [NCI DCTD website](#) and/or the [OHAM website](#) to learn more about the various program goals, research priorities, and strategies developed to fight cancer. Applications submitted to this FOA must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see [NOT-OD-15-015](#) for details) and provide specific clinical trial information as described in this FOA. This FOA does not accept phase III clinical trials in any area of cancer research;

Application Due Dates: [Standard dates](#) apply.

[PAR-21-035](#) (R01 Clinical Trial Required)

Cancer Prevention and Control Clinical Trials Grant Program

The National Cancer Institute (NCI) invites applications for support of investigator-initiated clinical trials related to the programmatic interests of the NCI Division of Cancer Prevention and/or the NCI Division of Cancer Control and Population Sciences that have the potential to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health. Applications submitted to this FOA must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see [NOT-OD-15-015](#) for details) and provide specific clinical trial information as described in this FOA and the application instructions. **Application Due Dates:** [Standard dates](#) apply.

[PAR-21-038](#) (R01 Clinical Trial Not Allowed)

[PAR-21-039](#) (R01 Basic Experimental Studies with Humans Required) Stephen I. Katz Early-Stage Investigator Research Project Grant

The Stephen I. Katz Early-Stage Investigator Research Project Grant supports an innovative project that represents a change in research direction for an early-stage investigator (ESI) and for which no preliminary data exist. Applications submitted to this Funding Opportunity Announcement (FOA) must not include preliminary data. Applications must include a separate attachment describing the change in research direction. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

Application Due Dates: January 26, 2022; May 26, 2022; September 27, 2022; January 26, 2023; May 26, 2023; September 26, 2023

[PAR-21-072](#) (R24 Clinical Trial Not Allowed) NIAAA Resource-Related Research Projects

The purpose of the R24 grant is to support investigator-initiated resources designed to provide materials and services to support and advance biomedical research on a national basis. An R24 resource grant mechanism is a non-hypothesis-driven activity to provide data, materials, tools, or services that are essential to making timely, high quality, and cost-efficient progress in a field. Hypothesis-driven research applications should not be submitted in response to this program announcement but to another mechanism that encourages this type of research. **Application Due Dates:** [Standard dates](#) apply.

[PAR-21-077](#) (R21/R33 - Clinical Trial Not Allowed)

Exploring the Scientific Value of Existing or New Sepsis Human Biospecimen Collections

This FOA invites applicants to submit proof of concept and scale-up studies to determine the scientific value of existing or new collections of human sepsis biospecimens with associated patient health record data. The biospecimens used in this study must be linked to clinical datasets useful for sepsis endotyping/stratification and characterization of disease trajectory, and the use of contemporary cutting-edge technologies in the analysis of these biospecimens is highly encouraged. The FOA will provide support for up to two years (R21

phase) for research planning activities and feasibility studies, followed by the possible transition to up to two additional years of scaled-up, expanded, or confirmatory research support (R33 phase). **Application Due Dates:** Standard dates apply

[PAR-20-315](#) (R00 Clinical Trial Optional)

Limited Competition: Lasker Clinical Research Scholars Transition Award

The Lasker Clinical Research Scholars Program supports research activities during the early-stage careers of independent clinical researchers. This FOA offers the opportunity for current Lasker awardees (Si2) to apply for the transition phase (R00) of the program. In the R00 phase, successful Si2 scholars will receive up to 5 years of NIH support for their research at an extramural research facility. **Application Due Dates:** Rolling receipt dates

[PAR-21-022](#) (R01 Clinical Trial Optional)

[PAR-21-023](#) (R34 Clinical Trial Optional)

Multi-Site Studies for System-Level Implementation of Substance Use Prevention and Treatment Services

This FOA seeks research projects that will test implementation strategies intended to achieve system-wide integration of evidence-based practices (interventions, guidelines, or service delivery models) to prevent or treat substance use disorders (broadly defined to include alcohol, tobacco and other drugs, as well as prescription medications). Areas of interest also include implementation of guidelines related to the appropriate use of opioids for pain management in individuals with or at risk for opioid use disorder. When clearly justified, applicants may propose to test strategies that are designed to achieve system-wide de-implementation of programs or clinical practices that are ineffective, unproven, wasteful or harmful.

Application Due Dates: July 19, 2022, November 15, 2022, July 19, 2023, November 15, 2023

[PAR-21-065](#) Curriculum or Methods Development (R25 Clinical Trial Not Allowed)

[PAR-21-066](#) Courses for Skills Development (R25 Clinical Trial Not Allowed)

[PAR-21-067](#) Research Experiences (R25 Clinical Trial Not Allowed) Cancer Research Education Grants Program

The over-arching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients. **Application Due Dates:** Standard dates apply.

[PAR-21-080](#) (R01 Clinical trial not allowed)

[PAR-21-081](#) (R01 Clinical Trial Optional)

Addressing the Etiology of Health Disparities and Health Advantages Among Immigrant Populations

Addressing the Etiology of Health Disparities and Health Advantages Among Immigrant Populations

The purpose of this FOA is to support innovative research to understand factors uniquely associated with the immigration experience that contribute to health disparities or health advantages among U.S. immigrant populations. Most research on immigrant health does not consider the factors and processes that pushed migration of members from groups or subsets of groups from one country to another. Little attention has been given to integration of the pre-existing experiences, (for example, starvation resulting from rapid environmental changes, changing food sources, exposures to toxic chemicals and pesticides), and how the experience of migration itself, or how the process of adjustment and adaptation to a new cultural, social, political and ecological environment may affect health outcomes. It is also important to consider the period(s) in the life course when immigration was experienced and how that experience may affect health outcomes. **Application Due Dates:** Standard dates apply.

[PAR-21-068](#) (R01 Clinical Trial Optional)

[PAR-21-069](#) (R21 Clinical Trial Optional)

Multidisciplinary Studies of HIV/AIDS and Aging

This FOA encourages applications at the intersection of HIV and aging by addressing two overarching objectives: 1) to improve understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) to improve approaches for testing, prevention, and treatment of HIV infection, and management of HIV-related comorbidities, co-infections, and complications in

different populations and cultural settings by applying our current understanding of aging science.

Application Due Dates: Standard dates apply.

[PAR-21-097](#) (R34 Clinical Trial Optional)

Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders

This FOA for R34 planning grant applications focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of this FOA is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and incidence of FASD and (2) interventions for FASD. It is expected that research conducted via this mechanism will consist of studies that are a pre-requisite for preparing and submitting subsequent applications for larger scale FASD prevention or intervention studies. **Application Due Dates:** February 17, 2022, June 17, 2022, October 18, 2022, February 17, 2023, June 19, 2023, October 17, 2023

[PAR-21-098](#) (R61/R33 Clinical Trial Optional)

Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders

This FOA focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of this FOA is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and the incidence of FASD and (2) interventions for FASD. These objectives will be accomplished with the Exploratory/Developmental Phased Award (R61/R33) mechanism, clinical trial optional. The R61 phase will support pilot studies or secondary data analysis for hypothesis development and feasibility, and research testing the hypotheses can be expanded in the R33 phase. The transition to the R33 phase will be determined by NIAAA program staff after evaluation of the achievement of specific milestones set for the R61 phase. Highest priority will be given to applications with clinical trials. **Application Due Dates:** February 17, 2022, June 17, 2022, October 18, 2022, February 17, 2023, June 19, 2023, October 17, 2023

[PAS-21-031](#) (R01 Clinical Trial Optional)

Priority HIV/AIDS Research within the Mission of the NIDDK

This Funding Opportunity Announcement (FOA) seeks to stimulate HIV/AIDS research within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) that align with the HIV/AIDS research priorities outlined by the NIH Office of AIDS Research (OAR). These priorities were most recently described in [NOT-OD-20-018 UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding](#). **Application Due Dates:** Standard dates apply.

[PAR-21-299](#) (K08 Clinical Trial Required)

[PAR-21-300](#) (K08 - Independent Clinical Trial Not Allowed)

NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity

This NCI-sponsored K08 award is specifically designed to enhance the diversity in the NCI-funded cancer research workforce by supporting eligible clinical scientists from diverse backgrounds, including groups that have been shown to be nationally underrepresented in health-related sciences and for those who are committed to a career in basic biomedical, behavioral or translational cancer research, including research on cancer health disparities. **Application Due Dates:** Standard dates apply.

[PAR-21-170](#) (K01 Independent Basic Experimental Studies with Humans Required)

[PAR-21-171](#) (K01 Clinical Trial Required)

[PAR-21-172](#) (K01 Clinical Trial Not Allowed)

Transition to Independent Environmental Health Research (TIEHR) Career Award

The Transition to Independent Environmental Health (TIEHR) Career Award is a 3-year bridge scholar development program for newly independent faculty who intend to pursue research careers in environmental health sciences. At the conclusion of the career development period the candidates are expected to demonstrate they can successfully compete for research funding in the environmental health sciences. **Application Due Dates:** Standard dates apply.

[PAR-21-301](#) (K22 Independent Clinical Trial Not Allowed)

[PAR-21-302](#) (K22 Clinical Trial Required)

NCI Transition Career Development Award to Promote Diversity

This Funding Opportunity Announcement (FOA) is a continuation of the NCI Transition Career Development Award to Promote Diversity (K22) to enhance the diversity in the NCI-funded cancer research workforce by supporting eligible individuals from diverse backgrounds, including groups that have been shown to be

nationally underrepresented in the biomedical, behavioral, social and clinical sciences. This award will provide "protected time" through salary and research support for 3 years beginning at the time when the candidate starts a tenure-track faculty position.

Application Due Dates: Standard dates apply.

[PAR-21-330](#) (U01 Clinical Trial Not Allowed)

Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research

The National Cancer Institute (NCI) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCO screened arm participants, and a onetime collection of buccal cells from both the screened and the control arm participants. Available data associated with the biospecimens includes demographic, diet, lifestyle, smoking, screening results, and other clinical data.

Application Receipt Dates: Multiple dates, see announcement.

[PAR-21-330](#) (U01 Clinical Trial Not Allowed)

Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research

The National Cancer Institute (NCI) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCO screened arm participants, and a onetime collection of buccal cells from both the screened and the control arm participants. Available data associated with the biospecimens includes demographic, diet, lifestyle, smoking, screening results, and other clinical data.

Application Receipt Dates: Multiple dates, see announcement.

[PAS-21-270](#) (R03 Clinical Trial Optional)

AIDS-Science Track Award for Research Transition

This funding opportunity announcement (FOA) seeks to facilitate the entry of both newly independent and early career investigators to the area of drug use and use disorder research and HIV/AIDS. This FOA, the AIDS-Science Track Award for Research Transition (A-START), encourages Small Research Grant (R03) applications to support research projects on drug use and/or use disorder and HIV/AIDS that can be carried out in a short period of time with limited resources. This FOA welcomes applications integrating substance use and/or substance use disorder (SUD) and HIV/AIDS across all areas of research supported by NIDA.

Application Receipt Dates: Multiple dates, see announcement.

[PAR-21-173](#) (R16 - Clinical Trial Not Allowed)

Support for Research Excellence – First Independent Research (SuRE-First) Award

The purpose of SuRE-First awards is to support research grants for faculty investigators who have not had prior independent external research grants. Since the SuRE-First Award is structured to best support a single PD/PI, multiple PD(s)/PI(s) are not allowed. PD(s)/PI(s) with similar or complementary research interests may apply separately. A PD/PI must have a full-time tenure-track (or equivalent) faculty appointment at the applicant institution and be eligible to apply for NIH research project grants.

Application Due Dates: Standard dates apply.

[PAR-21-271](#) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed)

[PAR-21-272](#) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 - Independent Clinical Trial Required)

[PAR-21-273](#) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 - Independent Basic Experimental Studies with Humans Required (BESH))

[PAR-21-277](#) Institutionally Focused Research Education Award to Promote Diversity (UE5 - Clinical Trial Not Allowed)

Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC)

The NIH Research Education Program (R25) supports research education activities in the mission areas of

the NIH. The overarching goal of this NIH MOSAIC UE5 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on 1. *Courses for Skills Development*; 2. *Mentoring Activities*.

Application Receipt Dates: Multiple dates, see announcement.

**[PAR-21-278](#) (R25 Clinical Trial Not Allowed) [PAR-21-279](#) (R25 Clinical Trial Not Allowed)
Cancer Research Education Grants Program - Research Experiences**

To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on **Research Experiences**. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients.

Application Due Dates: Standard dates apply.

**[PAR-21-307](#) (R01 Clinical Trial Required)
Dementia Care and Caregiver Support Intervention Research**

This Funding Opportunity Announcement (FOA) solicits mechanism-focused dementia care and caregiver support intervention development research at Stages I through V of the NIH Stage Model to address the care needs and promote the health, function, and well-being of persons with Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD) and of those providing their care.

Application Receipt Dates: Multiple dates, see announcement.

**[PAR-21-308](#) (R61/R33 – Clinical Trial Required)
Pragmatic Trials for Dementia Care and Caregiver Support**

This Funding Opportunity Announcement (FOA) will support pragmatic trials within Stage IV of the NIH Stage Model to improve dementia care across multiple dementia care settings that will: (1) be designed to address practical comparative questions faced by Alzheimer's disease (AD) and AD-related dementia (ADRD) patients, clinicians, and caregivers (both paid and unpaid); (2) include broad and diverse populations; and (3) be conducted in real-world settings with adequate sample size.

Application Receipt Dates: Multiple dates, see announcement.

**[PAR-21-306](#) (R50 Clinical Trial Not Allowed)
NCI Research Specialist (Clinician Scientist) Award**

The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional clinician scientists who want to continue to participate in the NCI clinical trials networks through leadership in the 1) development of national clinical trials, 2) implementation of NCI clinical trials in their institutions, and 3) national service to the NCI clinical trials networks through participation in the scientific review committees, monitoring committees and other activities, but not serve as principal investigators of research project grants.

Application Receipt Dates: Multiple dates, see announcement.

**[PAR-21-183](#) (UG3/UH3 Clinical Trial optional)
Developing Digital Therapeutics for Substance Use Disorders**

The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development of Digital Therapeutics (DTx) to treat Substance Use Disorders (SUDs). The primary objective of this FOA is to move DTx to their next step in the development process, with the ultimate goal of generating new, FDA authorized, disseminated treatments for SUDs. Applications may focus on the pre-clinical and/or clinical development and testing of new DTx or existing DTx developed for other indications.

Application Receipt Dates: Multiple dates, see announcement.

**[PAR-21-206](#) (R01 Clinical Trial Optional)
Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment** The purpose of this Funding Opportunity Announcement (FOA) is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and

methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes.

Application Receipt Dates: Multiple dates, see announcement.

PAR-21-208 (R21 Clinical Trial Optional) Cutting-Edge Basic Research Awards (CEBRA)

The proposed research should: 1. develop, and/or adapt, revolutionary techniques or methods for addiction research or that show promising future applicability to SUD research; and /or 2. test an innovative and significant hypothesis for which there are scant precedent or preliminary data and which, if confirmed, would transform current thinking. The program supports high-risk and potentially high-impact research that is underrepresented or not included in NIDA's current portfolio that has the potential to transform SUD research. **Application Receipt Dates:** Multiple dates, see announcement.

PAR-21-196 (R25 Independent Clinical Trial Not Allowed) Innovative Programs to Enhance Research Training (IPERT)

The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral, and clinical research needs. this FOA will support creative educational activities with a primary focus on: ***Courses for Skills Development; Mentoring Activities.*** **Application Due Dates:** October 14, 2022, October 13, 2023

PAR-21-197 (UG3/UH3 Clinical Trial Required)

NIDCR Behavioral and Social Intervention Clinical Trial Planning and Implementation Cooperative Agreement

The purpose of this Funding Opportunity Announcement (FOA) is to encourage UG3/UH3 phased cooperative agreement research applications to plan and implement behavioral and social intervention clinical trials. Studies appropriate for this announcement include clinical trials to develop and test behavior change interventions related to dental, oral, or craniofacial conditions. Awards made under this FOA will initially support a milestone-driven planning phase (UG3) for up to 2 years, with possible transition to a clinical trial implementation phase (UH3) of up to five years. **Application Due Dates:** Multiple dates, see announcement.

PAR-21-207 (R01 Clinical Trial Optional)

Mechanism-Focused Research to Promote Adherence to Healthful Behaviors to Prevent Mild Cognitive Impairment (MCI) and Alzheimer's Disease and Related Dementias

This FOA invites R01 applications for ancillary studies that address psychological and interpersonal mechanisms driving adherence to behavior or lifestyle change relevant to the prevention of cognitive decline, Mild Cognitive Impairment (MCI), and Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). This FOA will specifically support ancillary studies to ongoing, early- to late-stage clinical intervention trials. **Application Due Dates:** Multiple dates, see announcement.

PAR-21-250 (R21/R33 Clinical Trial Optional)

Mechanisms of Alcohol Tolerance

The intent of this FOA is to: (1) develop hypotheses about cellular, molecular or network mechanisms that regulate sensitivity and tolerance to alcohol, and (2) develop quantitative models to predict the development of tolerance and the progression to alcohol use disorder. These objectives will be accomplished with a Phased Innovation (R21/R33) mechanism, clinical trial optional, in which secondary data analysis or pilot studies can occur during the R21 phase, and research testing the hypotheses can be expanded in the R33 phase. **Application Due Dates:** Multiple dates, see announcement.

PAR-22-072 (R01 Clinical Trial Not Allowed)

Measures and Methods to Advance Research on Minority Health and Health Disparities-Related Constructs

The objective of this initiative is to produce knowledge that can inform the field about the types of measurement approaches that may be most suitable for different health disparities-related research questions or specific populations, settings, or contexts. Projects are encouraged to use multiple data sources across different levels and across multiple sectors when appropriate. **Application Due Dates:** February 05, 2022, February 05, 2023, February 05, 2024

[PAR-21-251](#) (K43 Independent Clinical Trial Required)

[PAR-21-252](#) (K43 Independent Clinical Trial Not Allowed) Emerging Global Leader Award

The purpose of the Fogarty Emerging Global Leader Award is to provide research support and protected time (three to five years) to an early career research scientist from a low- or middle-income country (LMIC) who holds a junior faculty position at an LMIC academic or research institution, as defined by the World Bank (<http://data.worldbank.org/about/country-classifications/country-and-lending-groups>, including “low-income,” “lower-middle-income,” and “upper-middle-income” countries). This intensive, mentored research career development experience is expected to lead to an independently funded research career at the LMIC institution or in another LMIC. **Application Due Dates:** November 3, 2022, November 3, 2023

NIH Funding Opportunities: Program Announcements (PA)

The following opportunities have standard due dates unless noted otherwise:

[PA-22-049](#)

AHRQ Patient-Centered Outcomes Research (PCOR) Mentored Research Scientist Career Development Award (K01)

Expiration Date: March 13, 2025

[PA-22-050](#)

AHRQ Patient-Centered Outcomes Research (PCOR) Mentored Clinical Scientist Career Development Award (K08)

Expiration Date: March 13, 2025

[PA-22-051](#)

AHRQ Mentored Career Enhancement Awards for Established Investigators in Patient-Centered Outcome Research (K18)

Expiration Date: July 13, 2025

Individual Actions for Sustainability

Pay Attention to Labels

- ✓ From coffee to fruit to clothing, there are some clear leaders when it comes to minimizing your impact on wildlife and the planet.
- ✓ If you're a coffee drinker, look for “shade-grown” coffee, which is grown while keeping forest habitats intact for migratory birds and other species.
- ✓ Choose Fair Trade certified goods, when possible, to support companies dedicated to sustainable production and paying laborers a fair wage.
- ✓ Buy organic food whenever possible; it may cost a little more, but it keeps harmful pesticides out of our land and water, protecting farm workers, wildlife, and your family.

For more information on RAS services, visit our website at sphhp.buffalo.edu/ras